about
Type I interferons for induction of remission in ulcerative colitisFlavonoids in Inflammatory Bowel Disease: A ReviewOverlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?Neuroimmune pharmacological approachesLactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposesBotanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A ReviewEstimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study.Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial.JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4+ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.Zinc in gut-brain interaction in autism and neurological disorders.Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet?Matricellular Protein Periostin Mediates Intestinal Inflammation through the Activation of Nuclear Factor κB Signaling.Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.Local chemerin levels are positively associated with DSS-induced colitis but constitutive loss of CMKLR1 does not protect against development of colitisPlasma long noncoding RNA expression profile identified by microarray in patients with Crohn's disease.Results of the first survey for the current status of inflammatory bowel disease management in Asian countries.Intestinal anti-inflammatory effects of RGD-functionalized silk fibroin nanoparticles in trinitrobenzenesulfonic acid-induced experimental colitis in rats.Tolerance Limits, Self-understanding, and Stress Resilience in Integrative Recovery of Inflammatory Bowel DiseaseThe Microbiota and Epigenetic Regulation of T Helper 17/Regulatory T Cells: In Search of a Balanced Immune SystemMolecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.Probing the Association of Pancreatitis in Inflammatory Bowel Disease.Anti-inflammatory Effects of Fungal Metabolites in Mouse Intestine as Revealed by In vitro Models.Epithelial ER Stress in Crohn's Disease and Ulcerative Colitis.Actual Usage and Quality of Experimental Colitis Models in Preclinical Efficacy Testing: A Scoping Review.Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease.The Impact of Exclusive Enteral Nutrition (EEN) on the Gut Microbiome in Crohn's Disease: A Review.Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behçet's disease.Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease.Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity.Perceived medication adherence barriers mediating effects between gastrointestinal symptoms and health-related quality of life in pediatric inflammatory bowel disease.Characteristics of Fecal Microbiota in Pediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy.Clinical and Histologic Mimickers of Celiac Disease.Gynostemma pentaphyllum saponins attenuate inflammation in vitro and in vivo by inhibition of NF-κB and STAT3 signaling.Microbiota dysbiosis in inflammatory bowel diseases: in silico investigation of the oxygen hypothesis.Self-management education for rehabilitation inpatients suffering from inflammatory bowel disease: a cluster-randomized controlled trial.Oral Delivery of Nanoparticles Loaded With Ginger Active Compound, 6-Shogaol, Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis.A recombinant cystatin from Ascaris lumbricoides attenuates inflammation of DSS-induced colitis.Control of Intestinal Inflammation, Colitis-Associated Tumorigenesis, and Macrophage Polarization by Fibrinogen-Like Protein 2.Death Receptor 3 Signaling Controls the Balance between Regulatory and Effector Lymphocytes in SAMP1/YitFc Mice with Crohn's Disease-Like Ileitis.
P2860
Q24187202-D24DCEBA-E6D6-42A5-A4A5-C183374A5B09Q26748883-1D638FD7-0364-4C5B-9AF5-BC706F3AFA57Q26765219-F09385DE-8C2B-48B2-A16E-005C22403DB8Q26782927-36C31D23-8F95-45A2-BD49-92A4D2CCFF46Q26786083-CEF8CE7A-D509-4185-8FE1-29482FA3DF45Q26998841-C02703F7-BDB5-4A07-BA47-DD89F8413778Q31141014-2C9C19BE-00E7-4FBD-9872-27C9F1A10AA5Q31146183-E8E5985D-C58B-4AFF-AF9C-5F27B8DABE85Q33606202-3131540B-1C63-4F9C-A138-D9F23DD04E08Q33868659-E293A9B3-97DB-411C-83FF-FFE1C9B386A6Q34471938-741A4A5D-D29E-4F73-A192-63AEEFC64BC2Q35801931-1E2E747B-D42E-4841-A72A-2334B49864F4Q35927164-8ADFAE0E-FCF5-4E7B-BFE6-69F32FDEF27AQ35933419-096CB71F-CF62-4CB9-AFFA-08FE20D7EE69Q36036478-907B8BF2-9D86-4408-870D-617E659BF208Q36909245-6D7CAE1C-A86C-44CC-88DC-61633D8177D0Q37095793-5E0350ED-8C8E-4A55-8978-205D582E1940Q37413157-B16B8537-7E10-4873-8AD7-9394FBC1C22FQ37467983-809B9C5F-40A1-4708-B5E7-09A2C3D184E4Q37742909-7042F24E-1D85-42E6-BA81-C681B8C42E57Q38492052-60ECECBB-CB9E-48C3-B493-DA7C78EF3D0DQ38624953-2B570DCB-2F57-4C74-A00F-036EDB3DF995Q38694522-FD2AF794-05A4-44A6-A7A7-FEA6021B1723Q38763648-BF4530E7-D5F5-4846-A084-6F7E65EA3BB5Q38814827-23DE4E99-F134-49CB-B8CE-955198E46EDDQ39132618-E4F517C9-C692-4FE7-AE55-2E8201AB60BEQ39281074-9E6855E4-9975-46B9-BF93-A6C6C8BB8C49Q40438366-E08063FD-B847-4B71-8B5F-C686B9A1A986Q40874243-ADCE6CC1-B73A-405D-833E-D4F1FC85C99DQ41127262-0B31F5D9-184F-49D2-8B4E-D8636A4DD7C4Q45939232-D6ACAD9D-E5F1-4A1B-B86B-FE5C75488DF6Q46250258-BAF6C029-461C-4F77-9D09-1390A4D78C06Q46651005-0D45AF32-EF39-4C2E-A2E8-5AC55442558BQ47161618-CDF700A8-462A-4AF3-BDDB-3D97CC37396FQ47215602-4E7B9033-D484-48AE-B5BA-EA34726F10D2Q47655969-946CD22F-2C02-45F1-B235-BC8F3418710AQ47754415-DBC75171-54D0-4F25-AD24-33373A566AA7Q48125469-53AC13FC-7BA9-415B-925E-C9F8A54301ADQ49730998-3EB3AFC4-64BF-4D3F-8409-54B37A366CD5Q51739535-CFEE72D8-BCEA-4541-9B54-D6B9BE6C49B0
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Treatment of IBD: where we are and where we are going.
@en
type
label
Treatment of IBD: where we are and where we are going.
@en
prefLabel
Treatment of IBD: where we are and where we are going.
@en
P2860
P356
P1476
Treatment of IBD: where we are and where we are going.
@en
P2093
Charles N Bernstein
P2860
P304
P356
10.1038/AJG.2014.357
P407
P577
2014-12-09T00:00:00Z